aldeyra.com (ALDX) - Long-Term Debt to Capital Coefficient

Aldeyra Therapeutics, Inc. - graphic logo of issuer ALDX

The current price chart for Aldeyra Therapeutics (ALDX) reflects the dynamics of a company developing innovative therapies for ocular pathologies. Business growth relies on FDA approval and the efficacy of its drugs compared to analogues. Unique RASP inhibitors will ensure high margins due to low demand elasticity. Meanwhile, the indicator stands at 0.00, and stable working capital helps mitigate the risks of product launch delays.

aldeyra.com (ALDX): Long-Term Debt to Equity from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for Aldeyra Therapeutics Inc. (ALDX)

- stock price and consensus target price:
Quote Chart Aldeyra|ALDX - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Aldeyra Therapeutics, Inc.|ALDX - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Aldeyra Therapeutics|ALDX - Company Book Value|Market Value to Book Value aldeyra.com|ALDX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Aldeyra Therapeutics|ALDX - Long-Term Debt to Capital|Short-Term Debt to Capital Aldeyra|ALDX - Company Total Debt|Debt to Net Assets Ratio Aldeyra Therapeutics, Inc.|ALDX - Company Long-Term Debts|Short-Term Debt Aldeyra Therapeutics|Immediate Liquidity aldeyra.com
- net income and valuation ratios data:
ALDX - Net Profit
General company analysis:aldeyra.com - ALDX
Signature product of Aldeyra Therapeutics Inc.

Aldeyra Therapeutics (ALDX) focuses on expansion within the ocular therapy segment through the market launch of its innovative drug, reproxalap. The current long-term debt-to-equity ratio reflects the proportion of credit obligations exceeding one year relative to equity, determining the stability of financial leverage during business scaling. A decrease in this ratio indicates strengthening solvency, minimizing default risks during periods of market volatility.

Key competitors

Alcon Inc - Long-Term Liabilities to Equity|Long-Term Debt to Capital BLCO|GKOS (Glaukos Medical) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital APLS (Apellis Pharmaceuticals)|Long-Term Debt to Capital Belite Bio Pharma BLTE|OCUL - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient HROW (Harrow Inc)|Viridian Pharma (VRDN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio LENZ Corp|OCS (Oculis Holding) - Long-Term Debt to Capital|Long-Term Debt to Capital eyepointpharma.com|Long-Term Debt to Equity Ratio KOD (Kodiak Sciences)|KALA (kalarx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital IRD (Opus Genetics)|OKYO Pharma Ltd (OKYO) - Long-Term Liabilities to Capital|ADVM: Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital outlooktherapeutics.com|CLSD: Long-Term Debt to Capital|Long-Term Liabilities to Capital NovaBay Pharmaceuticals, Inc. (NBY)|Long-Term Debt to Equity Kiora Pharmaceuticals Inc.|Alimera (ALIM) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital EYEN|Long-Term Debt to Capital guardionhealth.com (GHSI)|Long-Term Debt to Equity Ocuphire Pharma OCUP|Opthea Ltd - Long-Term Debt to Equity